LDH and renal function are prognostic factors for long-term outcomes of multiple myeloma patients undergoing allogeneic hematopoietic stem cell transplantation.
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
24
11
2019
accepted:
04
02
2020
revised:
03
02
2020
pubmed:
19
2
2020
medline:
22
6
2021
entrez:
19
2
2020
Statut:
ppublish
Résumé
Allogeneic hematopoietic stem cell transplantation (allo-SCT) may offer a cure for selected patients with multiple myeloma (MM). Effective prognostic markers to guide patient selection are warranted. We retrospectively studied a cohort of 100 relapsed refractory MM patients who underwent allo-SCT. With a median follow-up of 12.2 years, median overall survival (OS) and progression-free survival (LFS) were 9.2 months and 5.6 months, respectively. 5-years OS and PFS were was 18.0% and 16.8%. The cumulative incidence of 5-years relapse was 45.9% and non-relapse mortality (NRM) 36.0%. In a multivariable Cox model, decreasing albumin, increasing lactate dehydrogenase (LDH), advanced disease, and mismatched donors were predictive of both reduced OS and PFS. The probability of 5-years OS was higher in patients with LDH below vs. the upper limit of normal (22% vs. 5%, p = 0.004). In the multivariable analysis, the hazard of NRM was increased with low albumin, mismatched donor type, and declining estimated glomerular filtration rate (eGFR). Patients with a low eGFR had a 5-year NRM incidence of 31% vs. 56% in patients with higher levels (p = 0.02). Graft-versus-host disease was not associated with improved outcomes. In conclusion, LDH, renal function, and albumin are highly informative of outcomes in MM patients treated with allo-SCT.
Identifiants
pubmed: 32066863
doi: 10.1038/s41409-020-0829-1
pii: 10.1038/s41409-020-0829-1
doi:
Substances chimiques
L-Lactate Dehydrogenase
EC 1.1.1.27
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1736-1743Références
Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516–20. https://doi.org/10.1182/blood-2007-10-116129 .
doi: 10.1182/blood-2007-10-116129
pubmed: 17975015
pmcid: 2254544
Anderson KC. Progress and paradigms in multiple myeloma. Clin Cancer Res. 2016;22:5419–27. https://doi.org/10.1158/1078-0432.CCR-16-0625 .
doi: 10.1158/1078-0432.CCR-16-0625
pubmed: 28151709
pmcid: 5300651
Miething CC. Clonal evolution in myeloma: a narrow road to remission. Haematologica. 2019;104:1292–3. https://doi.org/10.3324/haematol.2019.220152 .
doi: 10.3324/haematol.2019.220152
pubmed: 31257204
pmcid: 6601107
Gratwohl A, Baldomero H, Passweg J, Frassoni F, Niederwieser D, Schmitz N, et al. Hematopoietic stem cell transplantation for hematological malignancies in Europe. Leukemia. 2003;17:941–59. https://doi.org/10.1038/sj.leu.2402896 .
doi: 10.1038/sj.leu.2402896
pubmed: 12750709
Pidala J, Anasetti C, Jim H. Quality of life after allogeneic hematopoietic cell transplantation. Blood. 2009;114:7–19. https://doi.org/10.1182/blood-2008-10-182592 .
doi: 10.1182/blood-2008-10-182592
pubmed: 19336756
pmcid: 2710956
Gonsalves WI, Buadi FK, Ailawadhi S, Bergsagel PL, Chanan Khan AA, Dingli D, et al. Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. Bone Marrow Transpl. 2019;54:353–67. https://doi.org/10.1038/s41409-018-0264-8 .
doi: 10.1038/s41409-018-0264-8
Gahrton G, Svensson H, Cavo M, Apperly J, Bacigalupo A, Bjorkstrand B, et al. Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-8 at European Group for Blood and Marrow Transplantation centres. Br J Haematol. 2001;113:209–16.
doi: 10.1046/j.1365-2141.2001.02726.x
Bensinger WI, Buckner CD, Anasetti C, Clift R, Storb R, Barnett T, et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood. 1996;88:2787–93.
doi: 10.1182/blood.V88.7.2787.bloodjournal8872787
Gahrton G, Tura S, Ljungman P, Blade J, Brandt L, Cavo M, et al. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol. 1995;13:1312–22. https://doi.org/10.1200/JCO.1995.13.6.1312 .
doi: 10.1200/JCO.1995.13.6.1312
pubmed: 7751876
Maymani H, Lin P, Saliba RM, Popat U, Bashir Q, Shah N, et al. Comparison of outcomes of allogeneic hematopoietic cell transplantation for multiple myeloma using three different conditioning regimens. Biol Blood Marrow Transpl. 2019. https://doi.org/10.1016/j.bbmt.2019.01.009 .
Greil C, Engelhardt M, Ihorst G, Schoeller K, Bertz H, Marks R, et al. Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life. Haematologica. 2019;104:370–9. https://doi.org/10.3324/haematol.2018.200881 .
doi: 10.3324/haematol.2018.200881
pubmed: 30237266
pmcid: 6355495
Maffini E, Storer BE, Sandmaier BM, Bruno B, Sahebi F, Shizuru JA, et al. Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma. Haematologica. 2019;104:380–91. https://doi.org/10.3324/haematol.2018.200253 .
doi: 10.3324/haematol.2018.200253
pubmed: 30262560
pmcid: 6355483
Shimoni A, Hardan I, Ayuk F, Schilling G, Atanackovic D, Zeller W, et al. Allogenic hematopoietic stem-cell transplantation with reduced-intensity conditioning in patients with refractory and recurrent multiple myeloma: long-term follow-up. Cancer. 2010;116:3621–30. https://doi.org/10.1002/cncr.25228 .
doi: 10.1002/cncr.25228
pubmed: 20564132
Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transpl. 2009;15:1628–33. https://doi.org/10.1016/j.bbmt.2009.07.004 .
doi: 10.1016/j.bbmt.2009.07.004
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF III, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12.
doi: 10.7326/0003-4819-150-9-200905050-00006
Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transpl. 1995;15:825–8.
Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transpl. 2005;11:945–56. https://doi.org/10.1016/j.bbmt.2005.09.004 .
doi: 10.1016/j.bbmt.2005.09.004
Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328–46. https://doi.org/10.1016/S1470-2045(16)30206-6 .
doi: 10.1016/S1470-2045(16)30206-6
Heinzl H, Kaider A. Gaining more flexibility in Cox proportional hazards regression models with cubic spline functions. Computer Methods Prog Biomed. 1997;54:201–8.
doi: 10.1016/S0169-2607(97)00043-6
Carreras E, Dufour C, Mohty M, Kröger N. The EBMT handbook: hematopoietic stem cell transplantation and cellular Therapies. Springer; 2019.
Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol. 2006;24:929–36. https://doi.org/10.1200/JCO.2005.04.5807 .
doi: 10.1200/JCO.2005.04.5807
pubmed: 16432076
Rosinol L, Perez-Simon JA, Sureda A, de la Rubia J, de Arriba F, Lahuerta JJ, et al. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood. 2008;112:3591–3. https://doi.org/10.1182/blood-2008-02-141598 .
doi: 10.1182/blood-2008-02-141598
pubmed: 18612103
Lopez-Corral L, Caballero-Velazquez T, Lopez-Godino O, Rosinol L, Perez-Vicente S, Fernandez-Aviles F, et al. Response to novel drugs before and after allogeneic stem cell transplantation in patients with relapsed multiple myeloma. Biol Blood Marrow Transpl. 2019. https://doi.org/10.1016/j.bbmt.2019.04.026 .
doi: 10.1016/j.bbmt.2019.04.026
Sobh M, Michallet M, Gahrton G, Iacobelli S, van Biezen A, Schonland S, et al. Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party. Leukemia. 2016;30:2047–54. https://doi.org/10.1038/leu.2016.101 .
doi: 10.1038/leu.2016.101
pubmed: 27118410
pmcid: 27118410
Björkstrand B, Iacobelli S, Hegenbart U, Gruber A, Greinix H, Volin L, et al. Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up. J Clin Oncol. 2011;29:3016–22. https://doi.org/10.1200/JCO.2010.32.7312 .
doi: 10.1200/JCO.2010.32.7312
pubmed: 21730266
Lokhorst HM, van der Holt B, Cornelissen JJ, Kersten MJ, van Oers M, Raymakers R, et al. Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study. Blood. 2012;119:6219–25. https://doi.org/10.1182/blood-2011-11-393801 .
doi: 10.1182/blood-2011-11-393801
pubmed: 22442350
Kroger N, Einsele H, Derigs G, Wandt H, Krull A, Zander A. Long-term follow-up of an intensified myeloablative conditioning regimen with in vivo T cell depletion followed by allografting in patients with advanced multiple myeloma. Biol Blood Marrow Transpl. 2010;16:861–4. https://doi.org/10.1016/j.bbmt.2010.01.018 .
doi: 10.1016/j.bbmt.2010.01.018
Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet. 2019;394:29–38. https://doi.org/10.1016/S0140-6736(19)31240-1 .
doi: 10.1016/S0140-6736(19)31240-1
Corradini P, Cavo M, Lokhorst H, Martinelli G, Terragna C, Majolino I, et al. Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. Blood. 2003;102:1927–9. https://doi.org/10.1182/blood-2003-01-0189 .
doi: 10.1182/blood-2003-01-0189
pubmed: 12738666
Schilling G, Hansen T, Shimoni A, Zabelina T, Perez-Simon JA, Gutierrez NC, et al. Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma. Leukemia. 2008;22:1250–5. https://doi.org/10.1038/leu.2008.88 .
doi: 10.1038/leu.2008.88
pubmed: 18418408
Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33:2863–9. https://doi.org/10.1200/JCO.2015.61.2267 .
doi: 10.1200/JCO.2015.61.2267
pubmed: 26240224
pmcid: 26240224
Gyurkocza B, Sandmaier BM. Conditioning regimens for hematopoietic cell transplantation: one size does not fit all. Blood. 2014;124:344–53. https://doi.org/10.1182/blood-2014-02-514778 .
doi: 10.1182/blood-2014-02-514778
pubmed: 4102707
pmcid: 4102707
Shouval R, de Jong CN, Fein J, Broers AEC, Danylesko I, Shimoni A, et al. Baseline renal function and albumin are powerful predictors for allogeneic transplantation-related mortality. Biol Blood Marrow Transpl. 2018;24:1685–91. https://doi.org/10.1016/j.bbmt.2018.05.005 .
doi: 10.1016/j.bbmt.2018.05.005
Kroger N, Shimoni A, Schilling G, Schwerdtfeger R, Bornhauser M, Nagler A, et al. Unrelated stem cell transplantation after reduced intensity conditioning for patients with multiple myeloma relapsing after autologous transplantation. Br J Haematol. 2010;148:323–31. https://doi.org/10.1111/j.1365-2141.2009.07984.x .
doi: 10.1111/j.1365-2141.2009.07984.x
pubmed: 19912215
Kroger N, Sayer HG, Schwerdtfeger R, Kiehl M, Nagler A, Renges H, et al. Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood. 2002;100:3919–24. https://doi.org/10.1182/blood-2002-04-1150 .
doi: 10.1182/blood-2002-04-1150
pubmed: 12393448
Rosinol L, Jimenez R, Rovira M, Martinez C, Fernandez-Aviles F, Marin P, et al. Allogeneic hematopoietic SCT in multiple myeloma: long-term results from a single institution. Bone Marrow Transpl. 2015;50:658–62. https://doi.org/10.1038/bmt.2014.320.
doi: 10.1038/bmt.2014.320.
Crawley C, Lalancette M, Szydlo R, Gilleece M, Peggs K, Mackinnon S, et al. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. Blood. 2005;105:4532–9. https://doi.org/10.1182/blood-2004-06-2387 .
doi: 10.1182/blood-2004-06-2387
pubmed: 15731182